Phase 2 Study: COXEN neoadjuvant biomarker trial in bladder cancer. https://t.co/zlRi85YeCM https://t.co/d7VRPa1Utz
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) https://t.co/DancR1a9Z7
RT @SWOG: A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; N…
RT @SWOG: A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; N…
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) https://t.co/3LY3RWfTH8 @SWOG
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
RT @sonpavde: Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate simila…
Neoadjuvant GCx4 v ddMVAC x4 for muscle-invasive #bladdercancer-@SWOG">@SWOG?src=hashtag_click">#bladdercancer-@SWOG S1314 randomized phase II trial (n=167)-pT0 rate similar 28% v 30% (P = 0.75)-COXEN scores did not predict response to specific regimen https://t.co/sKG1Y80v4L
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) https://t.co/a0C16TwL7R
RT @pcvblack: Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) thera…
Very proud of this incredible work! #bladdercancer
Flaig et al use data from a trial of neoadjuvant gemcitabine-cisplatin and #ddMVAC chemotherapy for #BladderCancer to refine a coexpression extrapolation algorithm and assess and develop biomarkers. @djmcconkey @UNCUroOnc @brunorbastos https://t.co/MHJjy
RT @pcvblack: Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) thera…
RT @pcvblack: Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) thera…
RT @pcvblack: Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) thera…
RT @pcvblack: Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) thera…
Great to see this in print. Congratulations to study team for pulling off an RCT (S1314) in biomarker-directed (COXEN) therapy for MIBC! @ThomasFlaig @SWOG #bladdercancer https://t.co/bUYs28l2Ao
A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695) https://t.co/p4RVqjcZor